Couldn't be more proud of our mighty team for this milestone!
We are thrilled to announce the early completion of patient enrollment for our SynAIRgy Phase 3 study of AD109, our investigational oral treatment for obstructive sleep apnea (OSA). 🎉 A heartfelt thank you to all the patients who are participating in this crucial trial and to the dedicated staff at our trial sites. Your commitment is bringing us closer to potentially redefining the standard of care for OSA. We know more treatment options are desperately needed. AD109 aims to address the root cause of OSA, and our mission is to make it become the first FDA-approved oral therapy to enhance oxygenation and improve patient outcomes. Stay tuned for more updates as we continue on this journey to transform OSA treatment. #OSA #SleepApnea #AD109 #ClinicalTrials